| Bioactivity | Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor[1][2]. | ||||||||||||
| Invitro | Terevalefim (ANG-3777) (0-10 μM) significantly inhibited cancer cells proliferation in HUVECs[2]. Cell Viability Assay[2] Cell Line: | ||||||||||||
| In Vivo | Terevalefim (ANG-3777) decreases apoptosis, increases proliferation, and promotes organ repair and function in animal models[1].Terevalefim (ANG-3777, 40 mg/kg, IP) phosphorylates the c-Met receptor in rats[2]. Animal Model: | ||||||||||||
| Name | Terevalefim | ||||||||||||
| CAS | 1070881-42-3 | ||||||||||||
| Formula | C9H8N2S | ||||||||||||
| Molar Mass | 176.24 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jonathan S Bromberg, et al. Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. Transplantation. 2021 Feb 1;105(2):443-450. [2]. Latha Paka, et al. The Effect of ANG-3777 on Hepatocyte Growth Factor Receptor, c-MET Signaling. American Transplant Society. |